Evidence map›Paper›PMID 24420674›Full record

ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2014

Diffuse intrinsic pontine glioma in children and adolescents: a single-center experience.

Stefano Gabriele Vallero, Daniele Bertin, Maria Eleonora Basso, Laura Stefania Pittana, Anna Mussano, Franca Fagioli

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. The trends in diagnosis, management, and care of patients with diffuse intrinsic pontine gliomas: Perspectives from a tertiary care hospital of pakistan.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Article
  3. Article
  4. Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.Journal of pediatric hematology/oncology · 2016
    Review
  5. Pediatric thalamic tumors in the MRI era: a Canadian perspective.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016
    Article
  6. Has hypofractionated radiotherapy become the standard of care in pediatric DIPG?Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2015
    Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Stefano Gabriele ValleroPediatric Oncohematology, Stem Cell Transplantation and Cell Therapy Division, A.O. Città della Salute e della Scienza-Ospedale Infantile "Regina Margherita", Piazza Polonia, 94, 10126, Turin, Italy, stefano.vallero@gmail.com.
Daniele Bertin
Maria Eleonora Basso
Laura Stefania Pittana
Anna Mussano
Franca Fagioli
Ospedale Regina Margherita · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with diffuse intrinsic pontine glioma (DIPG) have a very poor prognosis. Only radiotherapy (XRT) has proven to be effective in delaying the disease progression. Several chemotherapy schedules have been applied so far, but none demonstrated significant improvements in progression and survival.

methodsWe retrospectively analyzed the clinical data of children diagnosed with DIPG at our center (Pediatric Hospital "Regina Margherita," Turin, Italy) between 1999 and 2013. Progression-free survival (PFS) and overall survival (OS) were used to describe the outcomes.

resultsTwenty-four children were included in our report. Patients diagnosed before March 2003 (n = 12) were treated with XRT and vincristine (VCR); the remaining 12 patients received XRT and temozolomide (TMZ). Progression-free survival was 18.8 % at 1 year (SE = 7.6 %), while overall survival was 44.1 % at 1 year (SE = 9.9 %). Median PFS was 8.1 months, whereas median OS was 11.2 months. No statistically significant difference in PFS or OS was evidenced between the two treatment groups.

conclusionRadiotherapy followed by VCR or TMZ allows obtaining results that are in line with previous reports, with no advantages over other similar treatment schedules. DIPGs are challenging tumors with a dismal outcome. Further research and newer therapies are urgently needed in order to achieve improvements in survival.

Indexed as

AdolescentAntineoplastic Agents, AlkylatingBrain Stem NeoplasmsChildDacarbazineFemaleGliomaHumansMalePonsRetrospective StudiesSurvival AnalysisTemozolomideAntineoplastic Agents, AlkylatingDacarbazineTemozolomide

Identifiers

PMID24420674
OpenAlexW2085255313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.